Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307675 | 0.86 | HTR1A (0.40) | ALDH1A1MAPTTHRBCACNA1GDRD2 | |
| SCHEMBL12307669 | 0.84 | POLB (0.39) | ALDH1A1MAPTTHRBCACNA1GKMT2A | |
| SCHEMBL12307660 | 0.83 | CACNA1G (0.40) | ALDH1A1MAPTCACNA1GKMT2AEGFR | |
| SCHEMBL12307618 | 0.81 | KMT2A (0.45) | ALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL12307663 | 0.81 | KCNQ2 (0.54) | ALDH1A1CACNA1GKMT2A | |
| SCHEMBL12307489 | 0.79 | KMT2A (0.39) | ALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL12334182 | 0.78 | PARP1 (0.38) | ALDH1A1MAPTDRD2DRD3HSD17B10 | |
| SCHEMBL12307647 | 0.78 | USP2 (0.48) | ALDH1A1KMT2AEGFR | |
| SCHEMBL12307674 | 0.77 | KCNQ2 (0.49) | ALDH1A1MAPTCACNA1GDRD2DRD3 | |
| SCHEMBL12307639 | 0.76 | KMT2A (0.44) | ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2327704-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | Shionogi&Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | ALDH1A1 3559/4885MAPT 4347/4885THRB 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.